Thioparib inhibits homologous recombination repair, activates the type I IFN response, and overcomes olaparib resistanceLi‐Min Wang, Jin‐Xue He|EMBO Molecular Medicine|2023Cited by 42
Novel PARP1/2 inhibitor mefuparib hydrochloride elicits potent <i>in vitro</i> and <i>in vivo</i> anticancer activity, characteristic of high tissue distributionJin‐Xue He, Ze‐Hong Miao|Oncotarget|2016Cited by 41
Glycogen synthase kinase 3β inhibition synergizes with PARP inhibitors through the induction of homologous recombination deficiency in colorectal cancerNing Zhang, Jin‐Xue He|Cell Death and Disease|2021Cited by 32
GSK3β Inhibition Synergizes with PARP Inhibitors through the Induction of Homologous Recombination Deficiency in Colorectal CancerNing Zhang, Jin‐Xue He|Research Square|2020Cited by 0